



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

<b>Reagent:</b>	Jurkat LTR-GFP CCR5+ Cells (JLTRG-R5)
<b>Catalog Number:</b>	11586
<b>Lot Number:</b>	098167
<b>Release Category:</b>	C
<b>Provided:</b>	1.82 x 10 <sup>6</sup> cells/vial. Viability, 95%.
<b>Cell Type:</b>	Derived from Jurkat Cells.
<b>Propagation Medium:</b>	RPMI 1640, 10% FBS
<b>Freeze Medium:</b>	50% FBS, 40% RPMI 1640, 10% DMSO
<b>Growth Characteristics:</b>	Cells have a doubling time of 24-48 hrs.
<b>Sterility:</b>	Negative for mycoplasma, bacteria and fungi.
<b>Description:</b>	JLTRG/JLTRG-R5 cells are derived from Jurkat cells, which have been stably transfected with an LTR-GFP construct. In the absence of HIV-1 infection or HIV-1 Tat expression the cells exhibit no GFP expression. JLTRG (Cat #11587) cells cannot be infected with R5 tropic virus, whereas JLTRG-R5 cells express low levels of CCR5 and are thus susceptible to infection with R5 tropic viruses.
<b>Special Characteristics:</b>	JLTRG-R5 and JLTRG (Cat #11587) cells are Jurkat T cell-based reporter cell lines. JLTRG cells express CD4 and CXCR4 whereas JLTRG-R5 cells express both HIV-1 co-receptors, CXCR4 and CCR5 and are derived as a spontaneously occurring sub-clone of JLTRG cells. Both cell lines provide the convenience of using enhanced green fluorescence protein (eGFP) as a direct and quantitative marker of HIV-1 infection or HIV-1 Tat expression.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**Recommended Storage:** Liquid Nitrogen

**Contributor:** Dr. Olaf Kutsch

**References:** Ochsenbauer-Jambor C, Jones J, Heil M, Zammit KP, Kutsch O. T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication. *Biotechniques*. 2006 Jan;40(1):91-100.

Kutsch O, Levy DN, Bates PJ, Decker J, Kosloff BR, Shaw GM, Priebe W, Benveniste EN. Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription. *Antimicrob Agents Chemother*. 2004 May;48(5):1652-63.

**NOTE:** Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Jurkat LTR-GFP CCR5+ Cells (JLTRG-R5)(Cat #11587), from Dr. Olaf Kutsch." Also include the reference cited above in any publications.

**Scientists at for-profit institutions or who intend commercial use of this reagent must contact: Dugald Hall, The UAB Research Foundation, 701 20th Street South, AB 770, Birmingham, AL 35294, 205/996-7578, dhall@uab.edu before the reagent can be released.**

**Last Updated** July 05, 2017

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.